Evaluation of patupilone as monotherapy in patients with advanced hepatocellular carcinoma (HCC)

被引:0
|
作者
Venook, A. P.
Poon, R.
Kang, Y. K.
Mok, T. S.
Chao, Y.
de Bedout, S.
Harbott, A.
Li, J.
Johri, A. R.
机构
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Univ Hong Kong, Queen Mary Hosp, Hong Kong, Peoples R China
[3] Asan Med Ctr, Seoul, South Korea
[4] Chinese Univ Hong Kong, Hong Kong, Peoples R China
[5] Vet Gen Hosp, Taipei, Taiwan
[6] Novartis Pharmaceut, E Hanover, NJ USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
15055
引用
收藏
页数:1
相关论文
共 50 条
  • [1] Complete Regression of Locally Advanced Hepatocellular Carcinoma (HCC) Following Sorafenib Monotherapy
    Kumar, Shiva
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S374 - S374
  • [2] Sunitinib monotherapy in patients with advanced hepatocellular carcinoma (HCC): Insights from a multidisciplinary phase II study
    Zhu, A. X.
    Sahani, D. V.
    di Tomaso, E.
    Duda, D. G.
    Catalano, O. A.
    Ancukiewicz, M.
    Blaszkowsky, L. S.
    Abrams, T. A.
    Ryan, D. P.
    Jain, R. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC).
    Wainberg, Zev A.
    Segal, Neil Howard
    Jaeger, Dirk
    Lee, Kyung-Hun
    Marshall, John
    Antonia, Scott Joseph
    Butler, Marcus
    Sanborn, Rachel E.
    Nemunaitis, John J.
    Carlson, Cheryl Ann
    Finn, Richard S.
    Jin, Xiaoping
    Antal, Joyce
    Gupta, Ashok Kumar
    Massard, Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Zhu, A. X.
    Finn, R. S.
    Mulcahy, M. F.
    Gurtler, J. S.
    Sun, W.
    Schwartz, J. D.
    Rojas, P.
    Dontabhaktuni, A.
    Youssoufian, H.
    Stuart, K. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Tislelizumab monotherapy for patients with previously treated advanced hepatocellular carcinoma (HCC): RATIONALE-208 Chinese subpopulation
    Ren, Z.
    Li, Z.
    Zhang, T.
    Fang, W.
    Hu, S.
    Pan, H.
    Yen, C.
    Hou, J.
    Chen, Y.
    Shao, G.
    Hsu, C.
    Bai, Y.
    Meng, Z.
    Hou, M.
    Xie, C.
    Liu, Y.
    Wu, J.
    Li, B.
    Chica-Duque, S.
    Cheng, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S255 - S255
  • [6] HEPATIC ARTERIAL INFUSION OF CETUXIMAB FOR PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
    Poggi, G.
    Montagna, B.
    Di Cesare, P.
    Riccardi, A.
    Teragni, C.
    Pozzi, E.
    Quaquarini, E.
    Bernardo, G.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S401 - S401
  • [7] Identification of novel phosphoproteomic biomarkers in patients with advanced hepatocellular carcinoma (HCC)
    Sarker, Debashis
    Pedicona, Federico
    Zen, Yoh
    Borek, Weronika E.
    Khorsandi, Shirin Elizabeth
    Christopher, Josie
    Karampera, Christina
    Dowe, Thomas
    Heaton, Nigel
    Cutillas, Pedro Rodriguez
    Dokal, Arran David
    Britton, David James
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] LINIFANIB IN ADVANCED HEPATOCELLULAR CARCINOMA (HCC) PATIENTS: A PHASE 2 TRIAL
    Toh, Han-Chong
    Chen, Pei-Jer
    Carr, Brian I.
    Knox, Jennifer J.
    Gill, Sharlene
    Qian, Jiang
    Qin, Qin
    Ricker, Justin L.
    Carlson, Dawn M.
    Yong, Wei Peng
    HEPATOLOGY, 2010, 52 (04) : 1166A - 1166A
  • [9] Outcomes and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma (HCC)
    Ziogas, Dimitris
    Thillai, Kiruthikah
    Papadatos-Pastos, Dionysios
    Chowdhury, Mahfuja Hussain Ruhe
    Korantzis, Ippokratis
    Manickavasagar, Thubeena
    Suddle, Abid
    O'Grady, John
    Heaton, Nigel
    Ross, Paul J.
    Sarker, Debashis
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Tolerability and activity of tepotinib in Asian patients with advanced hepatocellular carcinoma (HCC)
    Qin, Shukui
    Lim, Ho Yeong
    Ryoo, Baek-Yeol
    Li, Cindy
    Chen, Wenfeng
    Cheng, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)